Summary
Quest Diagnostics Incorporated, a global leader in diagnostic information services, reported net revenues of $7.7 billion in 2017. The company's strategy focuses on accelerating growth through partnerships, offering broad diagnostic innovation, becoming a consumer-friendly provider, and supporting population health with data analytics. Operational excellence is a key driver, with the company achieving significant cost savings through its Invigorate program, exceeding its initial target. Quest Diagnostics emphasizes its strengths in scale, innovation, customer experience, and medical expertise, positioning itself for continued leadership in the evolving healthcare landscape. Financially, the company demonstrates a commitment to shareholder returns through consistent dividend increases and share repurchases, returning over $2.6 billion to stockholders since 2012. Strategic acquisitions in 2017, including those in oncology and cardiovascular diagnostics, are aimed at expanding its service offerings and market position. While facing industry challenges such as reimbursement pressures and increasing competition, Quest Diagnostics leverages its comprehensive capabilities and extensive network to deliver value and improve health outcomes.
Financial Highlights
57 data points| Revenue | $7.40B |
| Cost of Revenue | $4.72B |
| Gross Profit | $2.68B |
| SG&A Expenses | $1.44B |
| Operating Expenses | $6.24B |
| Operating Income | $1.17B |
| Interest Expense | $153.00M |
| Net Income | $772.00M |
| EPS (Basic) | $5.63 |
| EPS (Diluted) | $5.50 |
| Shares Outstanding (Basic) | 137.00M |
| Shares Outstanding (Diluted) | 140.00M |
Key Highlights
- 1Quest Diagnostics generated $7.7 billion in net revenues in 2017, solidifying its position as a leading provider of diagnostic information services.
- 2The company's growth strategy centers on four key pillars: partnerships, broad innovation, consumer-friendliness, and population health support.
- 3Significant progress has been made in operational excellence, with the Invigorate cost-saving program exceeding its target, delivering over $1.3 billion in run-rate savings by the end of 2017.
- 4Quest Diagnostics is actively pursuing strategic acquisitions, completing several in 2017 to expand its capabilities in areas like precision diagnostics for oncology and cardiovascular disease management.
- 5The company remains committed to shareholder returns, evidenced by a consistent increase in its quarterly dividend and substantial share repurchases, totaling over $2.6 billion since 2012.
- 6Leveraging its extensive network and data assets, Quest Diagnostics is enhancing its health information technology solutions, including its Quanum platform, to provide actionable insights and improve healthcare efficiency.
- 7The company is well-positioned to address key industry trends such as an aging population, the rise of precision medicine, and the increasing demand for data-driven healthcare solutions.